Mundipharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MUNDIPHARMA
MUNDIPHARMA has one approved drug.
There are seven US patents protecting MUNDIPHARMA drugs.
Summary for Mundipharma
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Mundipharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | 9,526,835 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | 11,819,533 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | 11,712,459 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Mundipharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2680873 | ⤷ Start Trial |
| Japan | 2014516339 | ⤷ Start Trial |
| Japan | 6111447 | ⤷ Start Trial |
| Japan | 5809296 | ⤷ Start Trial |
| Lithuania | 2827710 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mundipharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2680873 | CA 2024 00025 | Denmark | ⤷ Start Trial | PRODUCT NAME: REZAFUNGIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER REZAFUNGINACETAT; REG. NO/DATE: EU/1/23/1775 20231222 |
| 2680873 | CR 2024 00025 | Denmark | ⤷ Start Trial | PRODUCT NAME: REZAFUNGIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER REZAFUNGINACETAT; REG. NO/DATE: EU/1/23/1775 20231222 |
| 2680873 | C202430028 | Spain | ⤷ Start Trial | PRODUCT NAME: REZAFUNGINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN PARTICULAR ACETATO DE REZAFUNGINA; NATIONAL AUTHORISATION NUMBER: EU/1/23/1775; DATE OF AUTHORISATION: 20231222; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1775; DATE OF FIRST AUTHORISATION IN EEA: 20231222 |
| 2680873 | 202440021 | Slovenia | ⤷ Start Trial | PRODUCT NAME: REZAFUNGIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR REZAFUNGIN ACETATE; NATIONAL AUTHORISATION NUMBER: EU/1/23/1775; DATE OF NATIONAL AUTHORISATION: 20231222; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 2680873 | 122024000037 | Germany | ⤷ Start Trial | PREVIOUS REPRESENTATIVE: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- UND RECHTSANWAELTEN MBB, 22607 HAMBURG, DE; PRODUCT NAME: REZAFUNGIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE REZAFUNGINACETAT; AUTHORISATION NO/DATE: EU/1/23/1775 20231222 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
